Moderna stock surges on experimental cancer vaccine trial results

Moderna's share price nearly doubled on August 19–20, 2026 following announcement of promising results from a late-stage trial of an experimental, vaccine-based treatment that reduced skin cancer recurrence. Optimism about a potential breakthrough in personalized cancer treatment drove the stock rally.